AN2 Therapeutics (NASDAQ: ANTX) — Perfil da empresa, notícias e dados financeiros
AN2 Therapeutics is a biopharmaceutical company developing treatments for rare infectious diseases, focusing on chronic conditions.
AN2 Therapeutics
AN2 Therapeutics (NASDAQ:ANTX) is a biopharmaceutical company focused on developing treatments for patients with rare, chronic, and serious infectious diseases. With an emphasis on innovative research and drug development, their lead project involves advancing a novel therapy for the treatment of non-tuberculous mycobacterial (NTM) infections, a significant and growing global health concern. AN2 Therapeutics aims to address the unmet medical needs of patients suffering from these infections through rigorous clinical development programs and strategic collaborations. Their objective is to enhance quality of life for patients by providing effective and accessible treatments for complex infectious diseases that are often difficult to treat with existing medications.
Resumo
Operações
Produtos e/ou serviços de AN2 Therapeutics
- Development of novel treatments for chronic Gram-negative bacterial infections, emphasizing diseases with significant unmet medical needs.
- Research on antibiotic resistance mechanisms to create more effective antimicrobial therapies.
- Investigation into the microbiome's role in human health, aiming to develop treatments that restore balance.
- Advancement of precision medicine approaches for infectious disease treatment, focusing on individual patient needs and genetic factors.
- Collaboration with other organizations to speed up the development of vaccines and diagnostics for infectious diseases.
- Exploration of innovative drug delivery systems to improve the efficacy and reduce the side effects of antimicrobial agents.
equipe executiva do AN2 Therapeutics
- Eric E. EasomCo-Founder, CEO, President & Chairman of the Board
- Joseph S. ZakrzewskiCo-Founder & Independent Director
- Lucy O. DayCFO, & Principal Financial Officer
- Joshua M. EizenChief Legal Officer, COO & Corporate Secretary
- George Harrison TalbotCo-Founder & Senior Clinical Advisor
- Michael R. K. AlleyCo-founder & Head of Biology
- Sarah WilliamsVice President of Controller & Principal Accounting Officer
- Sanjay ChandaChief Development Officer
- Vince HernandezHead of Research
- Cameron TrenorChief Medical Officer
Últimas notícias sobre a AN2 Therapeutics
Principais indicadores financeiros
Resultados divulgados pela AN2 Therapeutics, em USD.
- Cap. de mercado
- 148,3 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -38,1 mi | -35,2 mi | |
| 0 | -54,6 mi | -51,3 mi | |
| 0 | -69,6 mi | -64,7 mi | |
| 0 | -42,3 mi | -41,5 mi |